Zacks Research Has Negative Outlook of IOVA FY2026 Earnings

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) – Analysts at Zacks Research cut their FY2026 earnings per share estimates for shares of Iovance Biotherapeutics in a research note issued on Friday, June 26th. Zacks Research analyst Team now anticipates that the biotechnology company will earn ($0.72) per share for the year, down from their previous estimate of ($0.71). The consensus estimate for Iovance Biotherapeutics’ current full-year earnings is ($0.62) per share. Zacks Research also issued estimates for Iovance Biotherapeutics’ Q4 2026 earnings at ($0.18) EPS.

Iovance Biotherapeutics (NASDAQ:IOVA) last issued its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.19) earnings per share for the quarter, hitting the consensus estimate of ($0.19). The company had revenue of $71.43 million for the quarter, compared to analysts’ expectations of $77.84 million. Iovance Biotherapeutics had a negative return on equity of 50.17% and a negative net margin of 123.92%.The firm’s revenue for the quarter was up 44.9% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.36) earnings per share.

Several other research firms have also commented on IOVA. UBS Group boosted their price objective on shares of Iovance Biotherapeutics from $2.00 to $4.00 and gave the stock a “neutral” rating in a research note on Thursday, March 5th. Truist Financial raised shares of Iovance Biotherapeutics to a “hold” rating in a research note on Wednesday, March 25th. Citizens Jmp raised Iovance Biotherapeutics from a “market perform” rating to a “market outperform” rating and set a $5.00 price objective for the company in a research report on Tuesday, March 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Iovance Biotherapeutics in a research report on Monday, April 6th. Finally, Chardan Capital decreased their target price on shares of Iovance Biotherapeutics from $16.00 to $14.00 and set a “buy” rating for the company in a report on Thursday, May 7th. Five research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $8.43.

Iovance Biotherapeutics Price Performance

NASDAQ:IOVA opened at $4.21 on Tuesday. The firm’s 50-day moving average price is $3.86 and its 200-day moving average price is $3.38. The company has a market capitalization of $1.88 billion, a PE ratio of -4.43 and a beta of 0.73. Iovance Biotherapeutics has a 1-year low of $1.67 and a 1-year high of $5.63.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Arcataur Capital Management LLC purchased a new stake in Iovance Biotherapeutics in the fourth quarter worth approximately $29,000. Granite Investment Partners LLC purchased a new stake in Iovance Biotherapeutics during the 4th quarter valued at $29,000. Motley Fool Asset Management LLC bought a new position in shares of Iovance Biotherapeutics during the 4th quarter valued at $29,000. M&T Bank Corp bought a new position in shares of Iovance Biotherapeutics during the 4th quarter valued at $31,000. Finally, SBI Securities Co. Ltd. boosted its stake in shares of Iovance Biotherapeutics by 169.1% in the 4th quarter. SBI Securities Co. Ltd. now owns 11,568 shares of the biotechnology company’s stock worth $32,000 after buying an additional 7,269 shares during the last quarter. Institutional investors own 77.03% of the company’s stock.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.